Clinical trial · Interventional
Phase II Study of Intravenous Rexin-G in Osteosarcoma
A Phase II Study of Intravenous Rexin-G in Recurrent or Metastatic Osteosarcoma
NCT00572130CI-TRIAL-00004994completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy. The objectives of the study are: (1) to evaluate the clinical effectiveness of intravenous injections of Rexin-G, a tumor-targeted gene vector, in controlling tumor growth and prolonging life, and (2) to evaluate its over-all safety.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rexin-G Dose 1 | Genetic | — | UNRESOLVED |
| Rexin-G Dose 2 | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Rexin-G Dose 1
- interventionNames
- Genetic: Rexin-G Dose 1
- type
- EXPERIMENTAL
- label
- Rexin-G Dose 2
- interventionNames
- Genetic: Rexin-G Dose 2
Primary outcomes (1)
- measure
- Clinical efficacy as measured by over-all response rates (either CR, PR or SD) by International PET criteria
- timeFrame
- 12-18 months
Secondary outcomes (1)
- measure
- Clinical efficacy as measured by progression-free survival greater than one month and over-all survival of 6 months or longer; clinical toxicity measures
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with recurrent or metastatic osteosarcoma who is considered refractory to known therapies. 2. Histologically or cytologically confirmed osteosarcoma that is measurable. 3. Adequate hepatic function: Total bilirubin \< 2.0 mg/dL (upper limit included); AST/ALT \< 2x institutional norm; alkaline phosphatase \< 2.5x upper limit of institutional norm unless the patient has extensive bone metastases. Patients with elevated alkaline phosphatase due to extensive liver disease will be excluded from study; albumin \> 3.0 mg/dL. There must be no substantial ascites. PT and PTT must be within normal limits. 4. Performance status must be \< 1 (ECOG 0-1) with a life expectancy of at least 3 months. 5. Hemoglobin \> 9 gms% 6. Absolute granulocyte count \> 1000/uL, and platelet count \> 100,000/uL. 7. Serum creatinine of less than 1.5 mg%. 8. There must be no plans for the patient to receive further cancer therapy from the date of enrollment until the completion of the 6-week follow-up visit. 9. Accessibility of peripheral or central IV line 10. Age \> 10 years 11. Patients will be off chemotherapy for a minimum of 4 weeks prior to initiation of therapy and should have recovered to Grade 1 or less toxicity. 12. The ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Prior malignancy, except for non-melanoma skin cancer, stage 1 breast cancer, CIS of cervix from which the patient has been disease-free for 5 years. 2. Woman who are pregnant or nursing 3. Fertile patients unless they agree to use barrier contraception (condoms and spermicide jelly) during the vector infusion period and for six weeks after infusion. Male patients must agree to use barrier contraception. 4. Patients who are transfusion dependent (more than one transfusion per month) 5. Patients with medical, psychiatric, or social conditions that would compromise successful adherence to this protocol. 6. Patient who do not meet the inclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.